Apathy and impulse control disorders in Parkinson's disease: A direct comparison

Parkinsonism and Related Disorders

Volumn 18, Issue 2, 2012, Pages 198-203

  Leroi, Iracema ^a,b   Andrews, Michelle ^b   McDonald, Kathryn ^a,c   Harbishettar, Vijay ^d   Elliott, Rebecca ^a   Byrne, E Jane ^a   Burns, Alistair ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b LANCASHIRE CARE NHS FOUNDATION TRUST   (United Kingdom)

^c SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Apathy; Behavioral disturbances; Impulse control disorders; Impulsivity; Neuropsychiatric; Parkinson's disease

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PRAMIPEXOLE; ROPINIROLE;

ADULT; AGED; ANXIETY; APATHY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; FEMALE; HUMAN; IMPULSE CONTROL DISORDER; MAJOR CLINICAL STUDY; MALE; MOTIVATION; PARKINSON DISEASE; PRIORITY JOURNAL; REWARD; RISK FACTOR;

AGED; APATHY; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMPULSE CONTROL DISORDERS; MALE; MIDDLE AGED; PARKINSON DISEASE; PSYCHIATRIC STATUS RATING SCALES;

EID: 84856226002     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2011.10.005     Document Type: Article

References (30)

1. Leroi I., Ahearn D.J., Andrews M., McDonald K.R., Byrne E.J., Burns A. Behavioral disorders, disability and quality of life in Parkinson's disease. Age Ageing 2011, 40(5):614-621.
2. Thobois S., Ardouin C., Lhommée E., Klinger H., Lagrange C., Xie J., et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010, 133(4):1111-1127.
3. Starkstein S.E., Mayberg H.S., Preziosi T.J., Andrezejewski P., Leiguarda R., Robinson R.G. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. JNeuropsych 1992, 4(2):134-139.
4. Pedersen K.F., Larsen J.P., Alves G., Aarsland D. Prevalence and clinical correlates of apathy in Parkinson's disease: a community-based study. Parkinsonism Relat Disord 2009, 15(4):295-299.
5. Voon V., Hassan K., Zurowski M., de Siuza M., Thomsen T., Fox S., et al. Prevalence of repetitive and reward-seeking behaviours in Parkinson disease. Neurology 2006, 67:1254-1257.
6. Weintraub D., Koester J., Potenza M.N., Siderowf A.D., Stacy M., Voon V., et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010, 67(5):589-595.
7. Voon V., Sohr M., Lang A.E., Potenza M.N., Siderowf A.D., Whetteckey J., et al. Impulse control disorders in Parkinson disease: a multicenter case-control study. Ann Neurol 2011, [online].
8. Robert P.H., Onyike C.U., Leentjens A.F.G., Dujardin K., Aalten P., Starkstein S., et al. Proposed diagnosic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders. Eur Psychiatry 2009, 24:98-104.
9. Czernecki V., Pillon B., Houeto J.L., Pochon J.B., Levy R., Dubois B. Motivation, reward, and Parkinson's disease: influence of dopatherapy. Neuropsychologia 2002, 40(13):2257-2267.
10. Leentjens A., Koester J., Fruh B., Shephard T., Barone P., Houben J. The effect of pramipexole on mood and motivational symptoms in parkinson's disease: a meta-analysis of placebo-controlled studies. Clin Ther 2009, 31(1):89-98.
11. Emre M., Aarsland D., Brown R., Burn D.J., Duyckaerts C., Mizuno Y., et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007, 22(12):1689-1707.
12. Giovannoni G., O'Sullivan J.D., Turner K., Manson A., Lees A. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. JNeurol Neurosurg Psychiatry 2000, 68:423-428.
13. Lesieur H.R., Blume S.B. The South Oaks Gambling Screen (SOGS): a new instrument for the identification of pathological gamblers. Am J Psychiatry 1987, 144:1184-1188.
14. First M.B., Spitzer R.L., Gibbon M., Williams J.B. Structured Clinical Interview for DSM-IV Axis I Disorders-Non-Patient Edition (SCID-I/NP), version 2.0 1996, New York State Psychiatric Institute, Biometrics Research, New York.
15. Mann R.E., Sobell L.C., Sobell M.B., Sobell D.P. Reliability of a family tree questionnaire for assessing family history of alcohol problems. Drug Alcohol Depend 1985, 15:61-67.
16. Marin R.S., Biedrzycki R.C., Firinciogullari S. Reliability and validity of the apathy evaluation scale. Psychiatry Res 1991, 38:143-162.
17. Patton J.H., Stanford M.S., Barratt E.S. Factor structure of the Barratt impulsiveness scale. JClin Psychol 1995, 51:768-774.
18. Fahn S., Elton R.L., UPDRS Development Committee Unified Parkinson's disease rating scale. Recent Developments in Parkinson's Disease 1987, 153-163. Macmillan, Florham Park, NJ. S. Fahn, C.D. Marsden, D.B. Calne, M. Goldstein (Eds.).
19. Tomer R., Aharon-Peretz J. Novelty seeking and harm avoidance in Parkinson's disease: effects of asymmetric dopamine deficiency. JNeurol Neurosurg Psychiatry 2004, 75:972-975.
20. Jankovic J., McDermott M., Carter J., Gauthier S., Goetz C., Golbe L., et al. Variable expression of Parkinson's disease. Neurology 1990, 40:1529-1534.
21. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67:361-370.
22. Cummings J.L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D.A., Gornbein J. The Neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994, 44:2308-2314.
23. Blair J.R., Spreen O. Predicting premorbid IQ: a revision of the national adult reading test. Clin Neuropsychol 1989, 3:129-136.
24. Verdejo-García A., Lawrence A.J., Clark L. Impulsivity as a vulnerability marker for substance-use disorders: review of findings from high-risk research, problem gamblers and genetic association studies. Neurosci Biobehav 2008, 32:777-810.
25. Potenza M.N., Voon V., Weintraub D. Drug insight: impulse control disorders and dopamine therapies in Parkinson's disease. Nat Clin Pract Neurol 2007, 3(12):664-667.
26. Giladi N., Weitzman N., Schreiber S., Shabtai H., Peretz C. New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: the role of dopamine agonist treatment and age at motor symptoms onset. JPsychopharmacol 2007, 21:501-506.
27. Uitti R.J., Tanner C.M., Rajput A.H., Goetz C.G., Klawans H.L., Thiessen B. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol 1989, 12(5):375-383.
28. Aarsland D., Andersen K., Larsen J.P., Lolk A., Nielsen H., Kragh-Sørensen P. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001, 56:730-736.
29. Leentjens A.F.G., Scholtissen B., Vreeling F.W., Verhey F.R.J. The serotonergic hypothesis for depression in Parkinson's disease: an experimental approach. Neuropsychopharmacology 2006, 31:1009-1015.
30. Soubrié P. Reconciling the role of central serotonin neurons in human and animal behaviour. Behav Brain Sci 1986, 9(2):319-335.